

UNITED STATES PATENT AND TRADEMARK OFFICE

(m)

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	Э.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/889,330		12/27/2001	Orville G. Kolterman	030639.0027.US1	2741
28381	7590	03/05/2004		EXAM	INER
ARNOLD & PORTER LLP ATTN: IP DOCKETING DEPT. 555 TWELFTH STREET, N.W.				LIU, SAMUEL W	
				ART UNIT	PAPER NUMBER
WASHINGTON, DC 20004-1206				1653	
				DATE MAILED: 03/05/200-	4

Please find below and/or attached an Office communication concerning this application or proceeding.

3	Application No.	Applicant(s)				
	09/889,330	KOLTERMAN ET AL.				
Office Action Summary	Examiner	Art Unit				
·	Samuel W Liu	1653				
The MAILING DATE of this communication a						
Period for Reply		ar are correspondence dedress				
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory perio - Failure to reply within the set or extended period for reply will, by statu. Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a resply within the statutory minimum of thirty d will apply and will expire SIX (6) MON te, cause the application to become AB.	eply be timely filed (30) days will be considered timely. HS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on <u>05</u>	March 2002.					
2a) This action is FINAL . 2b) ⊠ Th	is action is non-final.					
3) Since this application is in condition for allow	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D.	. 11, 453 O.G. 213.				
Disposition of Claims		·				
4) Claim(s) 1-83 is/are pending in the application	on.					
4a) Of the above claim(s) <u>none</u> is/are withdra						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8)⊠ Claim(s) <u>1-83</u> are subject to restriction and/o	or election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examir	ner.					
10) The drawing(s) filed on is/are: a) ac		by the Examiner.				
Applicant may not request that any objection to the	e drawing(s) be held in abeyan	ce. See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the corre	ction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).				
11)☐ The oath or declaration is objected to by the E	Examiner. Note the attached	Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C. §	119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
 Certified copies of the priority documer 	nts have been received.					
2. Certified copies of the priority documer						
3. Copies of the certified copies of the pri		received in this National Stage				
application from the International Burea	* **					
* See the attached detailed Office action for a lis	t of the certified copies not r	eceived.				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Su					
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 		/Mail Date formal Patent Application (PTO-152)				
Paper No(s)/Mail Date	6) Other:					

Application/Control Number: 09/889,330

Art Unit: 1653

DETAILED ACTION

Preliminary amendment filed 5 March 2002, which adds new claims 75-83 has been entered. The following Office action is applicable to the pending claims 1-83.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-42, drawn to a pharmaceutical formulation comprising an exendin peptide.

Group II, claims 43-81, drawn to a method of administering an exendin peptide to a subject in need and a method of increasing the subject sensitivity to exogenous or endogenous insulin.

The invention listed as Groups I and II do not related to a single general invention concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack he same or corresponding special technical features for the following reasons:

The method of claims 46 and 85 are obvious over Beeley, N. et al. (WO 9830231). Prior to the effective filing date of the instant application, Beeley et al. teach a pharmaceutical formulation comprising exendin or exendin agonist, iso-osmolality modifier, e.g., propylene glycol, polycols, dextrose (see pages 33-34) wherein the formulation has a pH of between 3.0 to 8.0 (see page 34). The above Beeley et al. teaching meets the limitation set forth in claim 1 of the current application. Thus, the claimed composition does not constitute a special technical feature linking all claims, as defined by PCT Rule 13.2 and 37 CFR 1.475(a), as a single contribution over the art, and a holding of lack of unity is therefore proper.

Application/Control Number: 09/889,330

Art Unit: 1653

۴

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder**.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicants are advised that reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samuel Wei Liu, Ph.D. whose telephone number is (571) 272-0949. The examiner can normally be reached Monday-Friday 9:00 -5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Christopher Low can be reached on (571) 272-0951. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communication and (703) 305-3014 for the after final communication. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Samuel Wei Liu, Ph.D.

February 26, 2003

Jane Cahane Carlson, PH.D

DOIMADDY EVABRISED